An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration
Cells · 2023
DOI: 10.3390/cells12071034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Amber K Virdi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIMH NIH HHS, NIH.
Abstract (Originalsprache)
HIV anti-retrovirals (ARVs) have vastly improved the life expectancy of people living with HIV (PLWH). However, toxic effects attributed to long-term ARV use also contribute to HIV-related co-morbidities such as heart disease, bone loss and HIV-associated neurocognitive disorders (HAND). Unfortunately, mouse models used to study the effects of ARVs on viral suppression, toxicity and HIV latency/tissue reservoirs have not been widely established. Here, we demonstrate an effective mouse model utilizing immune-compromised mice, reconstituted with infected human peripheral blood mononuclear cell (PBMCs). ARVs areincorporated into mouse chow and administered daily with combination ARV regimens includingAtripla (efavirenz, tenofovir disoproxil fumarate, and emtricitabine) and Triumeq (abacavir, dolutegravir and lamivudine). This model measures HIV-infected human cell trafficking, and ARV penetration throughout most relevant HIV organs and plasma, with a large amount of trafficking to the secondary lymphoid organs. Furthermore, the HIV viral load within each organ and the plasma was reduced in ARV treated vs. untreated control. Overall, we have demonstrated a mouse model that is relatively easy and affordable to establish and utilize to study ARVs’ effect on various tissues, including the co-morbid conditions associated with PLWH, such as HAND, and other toxic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL 60612, USA.
- Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Department of Internal Medicine, Division of Infectious Diseases, Rush Medical College, Chicago, IL 60612, USA.
- UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE 68182, USA.
- Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL 60612, USA.
Förderung
- NINDS NIH HHS
- NIMH NIH HHS
- NIH
Zitieren
APA
Virdi, A. K., Ho, S., Seaton, M. S., Olali, A. Z., Narasipura, S. D., Barbian, H. J., Olivares, L. J., Gonzalez, H., Winchester, L. C., Podany, A. T., Ross, R. D., Al-Harthi, L., & Wallace, J. (2023). An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration. Cells. https://doi.org/10.3390/cells12071034
Vancouver
Virdi AK, Ho S, Seaton MS, Olali AZ, Narasipura SD, Barbian HJ, et al. An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration. Cells. 2023. doi:10.3390/cells12071034
BibTeX
@article{Virdi2023,
author = {Virdi, Amber K and Ho, Sang and Seaton, Melanie S and Olali, Arnold Z and Narasipura, Srinivas D and Barbian, Hannah J and Olivares, Leannie J and Gonzalez, Hemil and Winchester, Lee C and Podany, Anthony T and Ross, Ryan D and Al-Harthi, Lena and Wallace, Jennillee},
title = {An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12071034}
}
EUVIMED